First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.

被引：0

作者：

Andre, Thierry

Elez, Elena

Lenz, Heinz-Josef

Jensen, Lars Henrik

Touchefeu, Yann

Van Cutsem, Eric

Garcia-Carbonero, Rocio

Tougeron, David

Mendez, Guillermo

Schenker, Michael

de la Fouchardiere, Christelle

Limon, Maria Luisa

Yoshino, Takayuki

Li, Jin

Aubin, Francine

Cela, Elvis

Chen, Tian

Lei, Ming

Jin, Lixian

Lonardi, Sara

机构：

[1] Sorbonne Univ, Paris, France

[2] Hop St Antoine, Assistance Publ Hop Paris, Paris, France

[3] Vall Hebron Univ Hosp, Barcelona, Spain

[4] Inst Oncol VHIO, Barcelona, Spain

[5] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Univ Hosp Southern Denmark, Vejle Hosp, Vejle, Denmark

[7] Ctr Hosp Univ Nantes, Nantes, France

[8] Univ Penn, Philadelphia, PA USA

[9] UCM, Hosp Univ 12 Octubre Imas12, Madrid, Spain

[10] Ctr Hosp Univ Poitiers Site Miletrie, Poitiers, France

[11] Hosp Univ Fdn Favaloro, Buenos Aires, Argentina

[12] Centrul Oncol Sf Nectarie, Craiova, Romania

[13] Univ Med & Pharm, Craiova, Romania

[14] Ctr Leon Berard, Lyon, France

[15] Hosp Univ Virgendel Rocio, Seville, Spain

[16] Natl Canc Ctr Hosp East Kashiwa, Chiba, Japan

[17] Shanghai East Hosp, Shanghai, Peoples R China

[18] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[19] Bristol Myers Squibb, Princeton, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.LBA143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA143

引用

页码：LBA143 / LBA143

页数：1

共 50 条

[1] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Andre, T.
Van Cutsem, E.
Elez, E.
Bennouna, J.
de la Fouchardiere, C.
Yoshino, T.
Jensen, L.
Mendez, G.
Li, J.
Goekkurt, E.
Abdullaev, S.
Chen, T.
Lei, M.
Lonardi, S.
ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
[2] A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW
Abdullaev, Sandzhar
Andre, Thierry
Lei, Ming
Lenz, Heinz-Josef
Novotny, James
Paulson, Andrew Scott
Tejpar, Sabine
Yamazaki, Kentaro
Ledeine, Jean-Marie
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[3] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study
Andre, Thierry
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Lenz, Heinz-Josef
Manzano Mozo, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Cela, Elvis
Yang, Yingsi
Lei, Ming
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA768 - LBA768
[4] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW
Lenz, Heinz-Josef
Lonardi, Sara
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Manzano, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Joshi, Rohit
Cela, Elvis
Chen, Tian
Jin, Lixian
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Andre, T.
Lonardi, S.
Lenz, H. J.
Jensen, L. H.
Van Cutsem, E.
Touchefeu, Y.
Garcia-Carbonero, R.
Tougeron, D.
Mendez, G. A.
Schenker, M.
de la Fouchardiere, C.
Limon, M. L.
Yoshino, T.
Li, J.
Manzano Mozo, J. L.
Cela, E.
Chen, T.
Lei, M.
Jin, L.
Elez Fernandez, M. E.
ANNALS OF ONCOLOGY, 2024, 35 : S451 - S452
[6] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
Overman, Michael J.
Lenz, Heinz-Josef
Andre, Thierry
Aglietta, Massimo
Wong, Mark Ka
Luppi, Gabriele
Van Cutsem, Eric
McDermott, Raymond S.
Hendlisz, Alain
Cardin, Dana Backlund
Morse, Michael
Neyns, Bart
Hill, Andrew Graham
Limon, M. Luisa
Garcia-Alfonso, Pilar
Krishnamurthy, Anuradha
Chen, Franklin
Abdullaev, Sandzhar
Soleymani, Samira
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
Andre, Thierry
Lonardi, Sara
Wong, Ka Yeung Mark
Morse, Michael
McDermott, Raymond S.
Hill, Andrew Graham
Hendlisz, Alain
Lenz, Heinz-Josef
Leach, Joseph W.
Moss, Rebecca Anne
Cao, Z. Alexander
Ledeine, Jean-Marie
Chan, Emily
Kopetz, Scott
Michael, J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] ONCOLOGISTS' PERCEPTIONS OF NIVOLUMAB PLUS IPILUMUMAB (NIVO plus IPI) AS FIRST-LINE (1L) TREATMENT FOR MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT (MSI-H/DMMR) METASTATIC COLORECTAL CANCER (MCRC)
Emidio, O.
Iqbal, Z.
Jeune-Smith, Y.
Feinberg, B.
VALUE IN HEALTH, 2024, 27 (12) : S351 - S351
[9] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
Lenz, H-J. J.
Van Cutsem, E.
Limon, M. L.
Wong, K. Y.
Hendlisz, A.
Aglietta, M.
Garcia-Alfonso, P.
Neyns, B.
Luppi, G.
Cardin, D.
Dragovich, T.
Shah, U.
Atasoy, A.
Postema, R.
Boyd, Z.
Ledeine, J-M.
Overman, M.
Lonardi, S.
ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
[10] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
Lonardi, S.
Andre, T.
Wong, K. Y. M.
Morse, M.
McDermott, R.
Hill, A.
Hendlisz, A.
Lenz, H.
Leach, J.
Moss, R. A.
Cao, Z. A.
Ledeine, J.
Kopetz, S.
Overman, M.
ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3

← 1 2 3 4 5 →